Meriem Hasmim

U1186-INSERM, 114 Rue Edouard Vaillant
Villejuif, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

A role for EMT in CD73 regulation in breast cancer.

A role for EMT in CD73 regulation in breast cancer.

Journal: Oncoimmunology
Published: December 05, 2022

SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC.

SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC.

Journal: Frontiers in immunology
Published: June 30, 2022

Editor's Note: ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy.

Editor's Note: ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy.

Journal: Cancer research
Published: April 15, 2022

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer.

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer.

Journal: Cancers
Published: February 02, 2021

Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies.

Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies.

Journal: Frontiers in oncology
Published: November 05, 2020

Firing up the cold tumors by targeting Vps34.

Firing up the cold tumors by targeting Vps34.

Journal: Oncoimmunology
Published: September 17, 2020

Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34.

Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34.

Journal: Autophagy
Published: September 07, 2020

Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy.

Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy.

Journal: Oncogene
Published: August 31, 2020

Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges.

Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges.

Journal: Cells
Published: July 24, 2019

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.

Journal: Science advances
Published: April 23, 2019

Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints.

Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints.

Journal: Cancer letters
Published: December 18, 2018

Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features.

Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features.

Journal: Oncoimmunology
Published: April 07, 2017
Showing 1-12 of 33

Last Updated: 09/26/2026